Business Wire
23 Jun 2026, 09:30 UTC · 12w ago
Verdict
Headline leans bullish. We score OGN +0.80 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish
Organon Canada and Henlius have launched BILDYOS and TUZEMTY biosimilars to the drugs PROLIA and XGEVA.
So whatThe introduction of biosimilars typically erodes market share and pricing power for the original brand-name drug manufacturers.
More negative than 80% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 86% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 86% of ticker scores this week
Organon is expanding its product portfolio and market access with the launch of two biosimilars.
More positive than 86% of ticker scores this week
Henlius is expanding access to its biosimilar treatments through a new partnership.
More negative than 82% of ticker scores this week
Amgen faces increased competition as biosimilars to its Prolia and Xgeva products are launched.
More positive than 78% of relationship scores this week
[mutual] Organon and Henlius are partners expanding access to denosumab biosimilars.
More positive than 57% of relationship scores this week
[mutual] Organon is launching biosimilars to compete with Amgen's PROLIA and XGEVA.
More positive than 57% of relationship scores this week
[mutual] Henlius is launching biosimilars to compete with Amgen's PROLIA and XGEVA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
+2.1%
Price agrees with the score
$13.68 vs $13.40 close before publication (Jun 22) · not market-adjusted
OGN chart →
